Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?
Abstract Long-term disease control is achieved in 80–90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse accounts about 10% in adults and 30–50% in children. Al...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2022-05-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44228-022-00006-6 |
| _version_ | 1797230202550484992 |
|---|---|
| author | Anna Komitopoulou I. Baltadakis I. Peristeri E. Goussetis |
| author_facet | Anna Komitopoulou I. Baltadakis I. Peristeri E. Goussetis |
| author_sort | Anna Komitopoulou |
| collection | DOAJ |
| description | Abstract Long-term disease control is achieved in 80–90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse accounts about 10% in adults and 30–50% in children. Allogeneic bone marrow transplantation offers remarkable benefit in cases with unfavorable outcome. Nevertheless, novel immunotherapeutic options have been approved for patients with adverse prognosis. Immunotherapeutic agents, nowadays, are preferred over standard chemotherapy for patients with relapsed or refractory B-ALL The mode of action, efficacy and safety data of immunotherapeutic agents released, indications and sequence of those therapies over the course of treatment, are herein reviewed. |
| first_indexed | 2024-04-24T15:24:44Z |
| format | Article |
| id | doaj.art-95e1a3be600149958fa534e7f5be87f4 |
| institution | Directory Open Access Journal |
| issn | 2590-0048 |
| language | English |
| last_indexed | 2024-04-24T15:24:44Z |
| publishDate | 2022-05-01 |
| publisher | SAABRON PRESS |
| record_format | Article |
| series | Clinical Hematology International |
| spelling | doaj.art-95e1a3be600149958fa534e7f5be87f42024-04-02T06:54:54ZengSAABRON PRESSClinical Hematology International2590-00482022-05-0141-2112010.1007/s44228-022-00006-6Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?Anna Komitopoulou0I. Baltadakis1I. Peristeri2E. Goussetis3Stem Cell Transplant Unit, “Agia Sofia Children’s Hospital”Department of Haematology and Bone Marrow Transplantation Unit, Evangelismos HospitalStem Cell Transplant Unit, “Agia Sofia Children’s Hospital”Stem Cell Transplant Unit, “Agia Sofia Children’s Hospital”Abstract Long-term disease control is achieved in 80–90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse accounts about 10% in adults and 30–50% in children. Allogeneic bone marrow transplantation offers remarkable benefit in cases with unfavorable outcome. Nevertheless, novel immunotherapeutic options have been approved for patients with adverse prognosis. Immunotherapeutic agents, nowadays, are preferred over standard chemotherapy for patients with relapsed or refractory B-ALL The mode of action, efficacy and safety data of immunotherapeutic agents released, indications and sequence of those therapies over the course of treatment, are herein reviewed.https://doi.org/10.1007/s44228-022-00006-6ImmunotherapyB-ALLTherapeutic choice |
| spellingShingle | Anna Komitopoulou I. Baltadakis I. Peristeri E. Goussetis Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? Clinical Hematology International Immunotherapy B-ALL Therapeutic choice |
| title | Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? |
| title_full | Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? |
| title_fullStr | Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? |
| title_full_unstemmed | Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? |
| title_short | Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? |
| title_sort | immunotherapy and allogeneic bone marrow transplantation in b acute lymphoblastic leukemia how to sequence |
| topic | Immunotherapy B-ALL Therapeutic choice |
| url | https://doi.org/10.1007/s44228-022-00006-6 |
| work_keys_str_mv | AT annakomitopoulou immunotherapyandallogeneicbonemarrowtransplantationinbacutelymphoblasticleukemiahowtosequence AT ibaltadakis immunotherapyandallogeneicbonemarrowtransplantationinbacutelymphoblasticleukemiahowtosequence AT iperisteri immunotherapyandallogeneicbonemarrowtransplantationinbacutelymphoblasticleukemiahowtosequence AT egoussetis immunotherapyandallogeneicbonemarrowtransplantationinbacutelymphoblasticleukemiahowtosequence |